Condition: Narcolepsy Type 1 · Narcolepsy Type 2 · Idiopathic Hypersomnia · Sponsor: Centessa Pharmaceuticals (UK) Limited
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
This description comes directly from the study's public registry record.
Orexin Centessa Program Lead · 617-468-5770 · ORX750-LTE@centessa.com
Always discuss trial participation with your own doctor first.
| Auburn, alabama | Auburn, Alabama, United States | Recruiting |
| Santa Ana, California | Santa Ana, California, United States | Recruiting |
| Miami, Florida | Miami, Florida, United States | Recruiting |
| Orlando, Florida | Orlando, Florida, United States | Recruiting |
| Winter Park, FL | Winter Park, Florida, United States | Recruiting |
| Stockbridge, GA | Atlanta, Georgia, United States | Recruiting |
| Atlanta, Georgia | Atlanta, Georgia, United States | Recruiting |
| Sterling Heights, Michigan | Sterling Heights, Michigan, United States | Recruiting |
| Hendersen, Navada | Henderson, Nevada, United States | Recruiting |
| Henderson, Nevada | Henderson, Nevada, United States | Recruiting |
| Denver, North Carolina | Denver, North Carolina, United States | Recruiting |
| Huntersville, North Carolina | Huntersville, North Carolina, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096674